Education
About Us
Working with TipRanks
Follow Us
Leap Therapeutics Inc (LPTX)
NASDAQ:LPTX
Top Page
Leap Therapeutics
(NASDAQ:LPTX)
42Neutral
Positive Factors
Efficacy in Niche Population
Encouraging data in a niche CRC population showed a higher objective response rate for sirexatamab compared to the control group.
Regulatory Pathway
Management believes the data in CRC is strong enough to initiate a conversation with FDA to seek a regulatory pathway based on the positive objective response data in DeFianCe.
Negative Factors
Market Potential
Sirexatamab did not show benefit in GEJ/G cancer, lowering the overall market potential of the drug.
Leap Therapeutics (LPTX) vs. S&P 500 (SPY)
Market Cap
$15.94M
Dividend YieldN/A
Average Volume (3M)686.09K
Price to Earnings (P/E)―
Beta (1Y)2.25
Revenue GrowthN/A
EPS Growth66.29%
CountryUS
Employees54
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.93
Shares Outstanding38,317,898
10 Day Avg. Volume269,271
30 Day Avg. Volume686,094
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$3.00Price Target Upside669.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Leap Therapeutics Business Overview & Revenue Model
Company DescriptionLeap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01 and TRX518. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.
How the Company Makes MoneyLeap Therapeutics generates revenue primarily through strategic collaborations, licensing agreements, and partnerships with other pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments, and royalties based on the successful development and commercialization of its drug candidates. The company may also receive funding from research grants and government contracts aimed at supporting its clinical trials and research initiatives. Additionally, Leap Therapeutics may engage in out-licensing its technology or drug candidates to other companies, which can provide another revenue stream.
Leap Therapeutics Financial Statement Overview
Summary
Leap Therapeutics faces financial challenges, with significant losses and cash flow issues being the primary concerns. Despite a strong gross profit margin and low leverage, negative net profit margins, deteriorating cash flows, and historical revenue volatility weigh heavily on financial performance.Income Statement
Leap Therapeutics shows a challenging income statement for TTM. The gross profit margin is 81.86%, indicating efficient cost management relative to revenue, but negative net profit and EBIT margins reflect significant losses. Revenue growth is positive from 0 in 2023 to $634,000 in 2024, but historical volatility is evident in revenue trends, indicating an unstable revenue base.45
Neutral
Balance Sheet
The balance sheet exhibits moderate stability with a debt-to-equity ratio of 0.01, indicating low leverage. The equity ratio of 75.26% suggests a strong equity position compared to total assets. However, the return on equity is negative due to consistent losses, highlighting profitability issues.55
Neutral
Cash Flow
Cash flow analysis reveals negative operating and free cash flows, indicating cash outflows exceed inflows. The free cash flow has deteriorated compared to the previous period, and the operating cash flow to net income ratio is negative, reflecting inefficient conversion of earnings to cash.40
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 634.00K | 0.00 | 0.00 | 1.50M | 1.50M | 0.00 | Gross Profit |
| 519.00K | -427.00K | -415.00K | 1.50M | 1.50M | -776.00K | EBIT |
| -68.75M | -87.04M | -56.76M | -41.43M | -28.54M | -33.45M | EBITDA |
| -67.26M | -80.99M | -53.98M | -40.01M | -26.81M | -32.10M | Net Income Common Stockholders |
| -64.59M | -81.41M | -54.60M | -40.59M | -27.51M | -32.90M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 16.28M | 70.64M | 65.50M | 114.92M | 52.07M | 3.89M | Total Assets |
| 19.07M | 72.83M | 70.35M | 117.91M | 54.37M | 7.45M | Total Debt |
| 0.00 | 262.00K | 678.00K | 469.00K | 552.00K | 1.03M | Net Debt |
| -16.28M | -70.38M | -64.82M | -114.45M | -51.52M | -2.87M | Total Liabilities |
| 9.90M | 12.68M | 11.49M | 10.02M | 7.72M | 9.20M | Stockholders Equity |
| 9.18M | 60.14M | 58.87M | 107.89M | 46.65M | -1.75M |
| Cash Flow | Free Cash Flow | ||||
| -55.17M | -43.75M | -49.04M | -35.16M | -25.96M | -27.00M | Operating Cash Flow |
| -55.17M | -43.75M | -49.04M | -35.16M | -25.96M | -26.90M | Investing Cash Flow |
| -100.72M | 48.97M | 0.00 | 0.00 | 25.00K | -85.00K | Financing Cash Flow |
| 37.08M | -30.00K | -210.00K | 98.03M | 74.00M | 14.82M |
Leap Therapeutics Technical Analysis
Negative
0.39
Price Trends
1.34
Negative
2.23
Negative
2.30
Negative
Market Momentum
-0.21
Negative
19.18
Positive
12.94
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LPTX, the sentiment is Negative. The current price of 0.39 is below the 20-day moving average (MA) of 0.46, below the 50-day MA of 1.34, and below the 200-day MA of 2.30, indicating a bearish trend. The MACD of -0.21 indicates Negative momentum. The RSI at 19.18 is Positive, neither overbought nor oversold. The STOCH value of 12.94 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LPTX.
Leap Therapeutics Risk Analysis
Leap Therapeutics disclosed 29 risk factors in its most recent earnings report. Leap Therapeutics reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Leap Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $881.05M | ― | -50.50% | ― | ― | 4.28% | |
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
44 Neutral | $114.38M | ― | -53.54% | ― | 145.37% | 57.01% | |
43 Neutral | $1.41B | ― | -26.84% | ― | 1.99% | 15.95% | |
42 Neutral | $15.94M | ― | -106.79% | ― | ― | 66.29% | |
42 Neutral | $110.00M | ― | -54.21% | ― | -78.55% | -0.92% |
* Healthcare Sector Average
Performance Comparison
LPTX
Leap Therapeutics
0.39
-1.81
-82.27%
CLDX
Celldex
21.17
-21.35
-50.21%
FATE
Fate Therapeutics
0.94
-6.29
-87.00%
ADAP
Adaptimmune Therapeutics
0.45
-1.01
-69.18%
REPL
Replimune Group
12.11
3.27
36.99%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.